Additional well-known prognostic markers, and at the same time predictors of therapeutic response, are ER and HER2 receptors [7,8,9], which is why determining the status of ER, PR and HER2 hormone receptors has been deemed as a necessary factor for making further decisions about breast cancer therapy [1]. The gene discussed is NR4A1; the disease is breast carcinoma.